OPDIVO 10 mg/mL concentrate for solution for infusion. clinical trials
6 indexed studies · 4 currently recruiting
- AuthorisedTherapeutic exploratory (Phase II)
Pilot study with Low-dose nivolumab in Advanced Neoplasms that are TMB-high
This early-stage study tests whether a lower dose of an immunotherapy drug called nivolumab can treat advanced cancers with many genetic changes, known as TMB-high tumours. Researchers want to see if this lower dose works well to shrink tumours while keeping side effects as low as possible.
For: TMB-high advanced neoplasmsBelgium - RecruitingTherapeutic exploratory (Phase II)
A PHASE 2, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICAL TRIAL OF ADP-A2M4CD8 MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH RECURRENT OVARIAN CANCERS (SURPASS-3 STUDY/ GOG-3084)
This study tests a new cell therapy called ADP-A2M4CD8, given alone or with an immunotherapy drug called nivolumab, for women with recurrent ovarian cancer. Researchers want to see if this treatment can shrink tumours and how safe it is for patients whose cancer has returned after previous treatments.
For: Recurrent ovarian cancer positive for MAGE-A4 in human leukocyte antigen (HLA)-A2+ subjectsSpain · France - RecruitingTherapeutic exploratory (Phase II)
A randomized phase II study of neo-adjuvant chemo/immunotherapy versus chemo-therapy alone for the treatment of locally advanced and potentially resectable non-small cell lung cancer (NSCLC) patients_NADIM II
This study looks at a new way to treat certain lung cancers before surgery. It compares whether adding an immunotherapy drug called OPDIVO to standard chemotherapy works better than chemotherapy alone for advanced non-small cell lung cancer.
For: Non-small cell lung cancer (NSCLC)Spain - RecruitingTherapeutic exploratory (Phase II)
A randomised phase II trial evaluating the efficacy of a nivolumab monotherapy lead in “window” or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in early stage triple negative breast cancers
This study looks at new ways to treat early-stage triple-negative breast cancer. It tests a drug called nivolumab alongside standard chemotherapy to see if it helps shrink tumours more effectively before surgery. The aim is to improve treatment results for this type of breast cancer.
For: Early stage triple negative breast cancerItaly - RecruitingPhase II and Phase III (Integrated)
Nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer: SANO-3 study
This study looks at a new drug called nivolumab for people with oesophageal cancer who have had previous treatment. It aims to see if nivolumab can help stop the cancer from coming back after surgery and chemotherapy/radiotherapy, by carefully monitoring patients for any return of the disease.
For: oesophageal cancerNetherlands - AuthorisedTherapeutic exploratory (Phase II)
NOCANO: Nivolumab as neoadjuvant immunotherapy for patients with Oral CANcer and identification of response-predictive biomarkers in tumour draining lymph NOdes
This study is testing a new medicine called nivolumab for people with a type of mouth cancer (oral cancer). We want to see how well it shrinks tumours before surgery and if we can find ways to predict who will benefit most.
For: Oral squamous cell carcinoma (OSCC)Sweden